Penumbra unveiled the results of a study on Sunday showing its device is superior to blood thinners in pulmonary embolism ...

Shares of medical device company Penumbra (NYSE:PEN) fell 5.5% in the afternoon session after the company announced results ...

The study found that the use of the company’s computer-assisted vacuum thrombectomy (CAVT) system, a form of mechanical ...

The first of its kind RCT in acute intermediate-high-risk PE used a surrogate endpoint, but more data are on the horizon.

Penumbra, Inc. (NYSE:PEN) ranks among the best medical device stocks to invest in. Needham raised Penumbra, Inc.

Thinking about what to do with Penumbra stock? You are not alone. Whether you are trying to decide if it is time to buy, hold, or move on, Penumbra offers a fascinating case study thanks to its recent ...

Trials from Edwards, Philips and Penumbra were among the most-watched studies at the annual cardiovascular meeting.

In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Penumbra (PEN – Research Report), with a price target of $224.00. Ryan Zimmerman has given his Buy rating due to a ...

Penumbra, Inc. announced that the results of the STORM-PE randomized controlled trial showed that mechanical thrombectomy using ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $309.08, with a ...

Penumbra reported Q4 sales of $315.52 million, up 10.8% Y/Y, beating estimates of $311.55 million. U.S. thrombectomy sales jumped 27.3%, driving global growth of 15.4%. Up Next: Get 5 Dark Horse ...

WASHINGTON -- It's a tiny vacuum cleaner for the brain: A new treatment for stroke victims promises to suction out clogged arteries in hopes of stopping the brain attack before it does permanent harm.